COEP_OUT_1 [2025-04-29 07:28:25 -0400] 6243 Bytes | 1636 tokens | Cum: 1636 tkns (20.45% of 8k)
==========================================================================

Much activity, there is. Coeptis Therapeutics (COEP), lifted from $8.97 to $9.38, it has. 7:28 AM on Tue Apr 29, 2025, it is. Wise we must be, quick we must act. Hmmm.

--- COMPANY PROFILE ---
Company: Coeptis Therapeutics (COEP)
IPO: 2022-10-31 (2 Years Ago)
Market Cap: $37,670,492
Shares Outstanding: 3,420,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Here’s a list of headlines for Coeptis Therapeutics:

Apr-25-25 08:33AM - Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement
Apr-17-25 08:38AM - COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology
Apr-15-25 08:33AM - NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives
Mar-11-25 08:34AM - Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline
Mar-07-25 08:37AM - COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
Mar-06-25 08:00AM - NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan
Feb-20-25 09:00AM - COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
Feb-20-25 09:00AM 07:27AM - COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
Feb-19-25 04:00PM - COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
Feb-13-25 08:39AM - COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups
Feb-06-25 08:08AM - COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
Jan-30-25 08:27AM - Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation
Jan-23-25 08:09AM - Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
Jan-22-25 08:00AM - Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
Jan-07-25 08:00AM - Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
Dec-27-24 08:15AM - Coeptis Therapeutics Announces Reverse Stock Split
Dec-26-24 08:15AM - Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
Dec-12-24 08:00AM - Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
Dec-03-24 08:15AM - Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
Nov-07-24 08:07AM - Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Oct-24-24 08:07AM - Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
Oct-15-24 08:07AM - Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-19T21:00:00Z - COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
B2 - 2025-01-23T13:09:00Z - Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
B3 - 2024-12-27T13:15:00Z - Coeptis Therapeutics Announces Reverse Stock Split
B4 - 2024-12-03T13:15:00Z - Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
B5 - 2024-11-07T13:07:00Z - Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
B6 - 2024-01-18T13:54:58Z - Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Coeptis Therapeutics (COEP).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

COEP_OUT_3 [2025-04-29 07:28:25 -0400] 926 Bytes | 240 tokens | Cum: 1878 tkns (23.47% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/19/3029129/0/en/COEPTIS-NexGenAI-Affiliates-Network-MarketLeverage-Announce-Strategic-Partnership-to-Revolutionize-AI-Powered-Affiliate-Marketing.htmlCOEPTIS and MarketLeverage have partnered to integrate AI technology with performance-based affiliate marketing strategies, aiming to provide advanced automation, data-driven insights, and seamless campaign optimization for affiliates, brands, and marketers.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_5 [2025-04-29 07:28:26 -0400] 917 Bytes | 284 tokens | Cum: 2164 tkns (27.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T22:13:55Z - The M&A Class Action Firm Investigates the Merger of Coeptis Therapeutics Holdings, Inc. - COEP...
A2 - 2025-04-28T19:33:32Z - BB's Stock Haven : $COEP - "We are excited to take this ste......
A3 - 2025-04-28T16:06:55Z - MOMO'S BREAKOUT BOARD : $COEP - In connection with the merger, C......
A4 - 2025-04-28T13:40:21Z - BB's Stock Haven : $COEP Coeptis Therapeutics Secures World......
A5 - 2025-04-25T20:36:02Z - U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.05% By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

COEP_OUT_7 [2025-04-29 07:28:26 -0400] 1181 Bytes | 331 tokens | Cum: 2497 tkns (31.21% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**The M&A Class Action Firm Investigates the Merger of Coeptis Therapeutics Holdings, Inc. - COEP**Date: 2025-04-28Source: {'uri': 'marketscreener.com', 'dataType': 'news', 'title': 'Market Screener'}URL: https://www.marketscreener.com/quote/stock/COEPTIS-THERAPEUTICS-HOLD-146105655/news/The-M-A-Class-Action-Firm-Investigates-the-Merger-of-Coeptis-Therapeutics-Holdings-Inc-COEP-49743060/NEW YORK, April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), relating to the proposed merger with Z Squared Inc. Under the terms of the agreement, holders of outstanding Z Squared shar

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_9 [2025-04-29 07:28:27 -0400] 1181 Bytes | 290 tokens | Cum: 2789 tkns (34.86% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): es will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines.

Click here for more https://monteverdelaw.com/case/coeptis-therapeutics-holdings-inc-coep/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.

No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmont

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_11 [2025-04-29 07:28:28 -0400] 991 Bytes | 281 tokens | Cum: 3072 tkns (38.40% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): [email protected] or by telephone at (212) 971-1341.

Contact:

Juan Monteverde, Esq.

MONTEVERDE & ASSOCIATES PC

The Empire State Building

350 Fifth Ave. Suite 4740

New York, NY 10118

United States of America

[email protected]

Tel: (212) 971-1341

Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-coeptis-therapeutics-holdings-inc--coep-302440243.html

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_13 [2025-04-29 07:28:29 -0400] 799 Bytes | 211 tokens | Cum: 3285 tkns (41.06% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-25 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Merger Agrmt

This section describes the material provisions of the Merger Agrmt (as defined below) but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by re...

S2 - 2025-03-27 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER. ##TABLE_END

As discussed elsewhere in this Annual Report on Form 10-K, pursuant to the Merger, we acquired our primary operating subsidiary Coeptis Therapeutics, Inc. The Merger was a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

COEP_OUT_15 [2025-04-29 07:28:30 -0400] 1181 Bytes | 290 tokens | Cum: 3577 tkns (44.71% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

Merger Agreement

This section describes the material provisions of the Merger Agreement (as defined below) but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1. Coeptis shareholders and other interested parties are urged to read such agreement in its entirety. Unless otherwise defined herein, the capitalized terms used below are defined in the Merger Agreement .

General Terms and Effects

On April 25, 2025, Coeptis Therapeutics Holdings, Inc. (Coeptis or the Purchaser), entered into an Agreement and Plan of Merger (the Merger Agreement) with CP Merger Sub Inc., a Wyoming corporation and wholly-owned subsidiary of Coeptis (Merger Sub), and Z Squared, Inc., a Wyom

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_17 [2025-04-29 07:28:31 -0400] 1181 Bytes | 273 tokens | Cum: 3852 tkns (48.15% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ing corporation (Z Squared).

Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, upon the consummation of the transactions contemplated by the Merger Agreement (the Closing), (i) Merger Sub will merge with and into Z Squared (the Merger) and (ii) Coeptis will immediately prior to the Merger effect a spin out of its biopharmaceutical operations (the Spin Out and, together with Merger and the other transactions contemplated by the Merger Agreement, the Transactions), with Z squared continuing as the surviving corporation in the Merger and becoming a wholly-owned subsidiary of Coeptis.

In the Merger, all shares of Z Squared common stock issued and outstanding immediately prior to the effective time of the Merger (other than those properly exercising any applicable dissenters rights under Wyoming law), will be converted into the right to receive a porti

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_19 [2025-04-29 07:28:31 -0400] 1181 Bytes | 275 tokens | Cum: 4129 tkns (51.61% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): on of the Merger Consideration (as defined below) and (ii) any other outstanding securities with the right to convert into or acquire equity securities of Z Squared will be terminated. At the Closing, Coeptis will change its name as mutually agreed upon by the Purchaser and Z Squared.

In connection with the Spin Out, all of Coeptis assets comprising its biopharmaceutical business will be assigned and contributed prior to Closing to one or more Spin Out Subsidiaries, which will then spin out to Coeptis stockholders of record on the record date established for the Coeptis Special Meeting (as defined below).

Merger Consideration

The aggregate Merger Consideration received by Z Squared security holders from Coeptis at the Closing will be a number of shares of Purchaser Common Stock that represents at Closing the Applicable Percentage of Purchasers issued and outstanding shares of Purcha

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_21 [2025-04-29 07:28:32 -0400] 1181 Bytes | 269 tokens | Cum: 4400 tkns (55.00% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ser Common Stock as calculated on a Fully-Diluted Basis

Representations and Warranties

The Merger Agreement contains a number of representations and warranties by each of Coeptis and Z Squared as of the date of the Merger Agreement and as of the date of the Closing. Many of the representations and warranties are qualified by materiality or Material Adverse Effect. Material Adverse Effect as used in the Merger Agreement means with respect to any specified person or entity, any fact, event, occurrence, change or effect that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse effect upon (a) the business, assets, liabilities, results of operations or condition (financial or otherwise) of such person or entity and its subsidiaries, taken as a whole, or (b) the ability of such person or entity or any of its subsidiaries on a timely basis t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_23 [2025-04-29 07:28:33 -0400] 1181 Bytes | 248 tokens | Cum: 4650 tkns (58.13% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): o consummate the transactions contemplated by the Merger Agreement or the ancillary documents to which it is a party or bound or to perform its obligations thereunder, in each case subject to certain customary exceptions.

Certain of the representations are subject to specified exceptions and qualifications contained in the Merger Agreement or in information provided pursuant to certain disclosure schedules to the Merger Agreement.

The representations and warranties made by Coeptis and Z Squared are customary for transactions similar to the Transactions.

2

No Survival

The representations and warranties of the parties contained in the Merger Agreement terminate as of, and do not survive, the Closing, and there are no indemnification rights for another partys breach. The covenants and agreements of the parties contained in the Merger Agreement do not survive the Closing, except thos

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_25 [2025-04-29 07:28:33 -0400] 790 Bytes | 179 tokens | Cum: 4831 tkns (60.39% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): e covenants and agreements to be performed after the Closing, which covenants and agreements will survive until fully performed.

Covenants of the Parties

Each party agreed in the Merger Agreement to use its commercially reasonable efforts to effect the Closing. The Merger Agreement also contains certain customary covenants by each of the parties during the period between the signing of the Merger Agreement and the earlier of the Closing or the termination of the Merger Agreement in accordance wit...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

COEP_OUT_27 [2025-04-29 07:28:39 -0400] 7275 Bytes | 2028 tokens | Cum: 6861 tkns (85.76% of 8k)
==========================================================================

This is our set of metrics for Coeptis Therapeutics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------+
| Volume: 197,267 | Perf Month: -3.65% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 71.01K | Perf Quarter: -30.36% | Short Float: 1.22% | ROE: -226.63% |
+--------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 2.79 | Index: - | Short Ratio: 0.50 | ROI: -199.44% |
+--------------------+-----------------------+------------------------+-------------------+
| RSI (14): 44.80 | Market Cap: 30.63M | Short Interest: 0.04M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| ATR (14): 1.15 | Shs Outstand: 3.41M | Beta: -0.66 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA20: -8.42% | Shs Float: 2.93M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA50: -11.93% | Inst Own: 0.32% | Sales past 5Y: -20.00% | Earnings: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA200: 38.54% | Insider Own: 14.11% | Employees: 7 | |
+--------------------+-----------------------+------------------------+-------------------+
| Perf Week: -19.87% | Insider Trans: 0.00% | Debt/Eq: 0.26 | |
+--------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading by Coeptis Therapeutics officers or majority shareholders (if available).

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by Deschamps Philippe (Unknown Title) on 2025-03-04
- Non-qualified Stock Options (right to buy): 5700 shares at $N/A (D)

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by Calise Chris (Unknown Title) on 2025-03-04
- Non-qualified Stock Options (right to buy): 5700 shares at $N/A (D)

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by Cochran Christopher P. (Unknown Title) on 2025-03-04
- Non-qualified Stock Options (right to buy): 5700 shares at $N/A (D)

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by DeSilva Tara (Unknown Title) on 2025-03-04
- Non-qualified Stock Options (right to buy): 5700 shares at $N/A (D)

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by Mehalick David (CEO and President) on 2025-03-04
- Non-Qualified Stock Options (right to buy): 28875 shares at $N/A (D)

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by Salkind Gene (Unknown Title) on 2025-03-04
- Non-qualified Stock Options (right to buy): 5700 shares at $N/A (D)

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by Sheehy Christine Elise (VP Compliance and Secy) on 2025-03-04
- Non-Qualified Stock Options (right to buy): 1000 shares at $N/A (D)

Inside Trans: Coeptis Therapeutics Holdings, Inc. (COEP) by Yerace Daniel Alexander (VP of Operations) on 2025-03-04
- Non-Qualified Stock Options (right to buy): 5000 shares at $N/A (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -9813601.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 8.97
Average Volume: 71953.5
30-Day High: 12.47
30-Day Low: 7.7

[Detailed Financials: TTM 2024]
- Total Assets: $8,908,660.00
- Total Liabilities: $5,041,434.00
- Total Equity: $3,867,226.00
- Current Assets: $1,051,292.00
- Current Liabilities: $4,513,309.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-9,813,601.00
- Gross Profit: $0.00
- Operating Income: $-10,054,488.00
- Earnings Per Share (EPS): -5.65

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0.00

[Detailed Financials: FY 2024]
- Total Assets: $8,908,660.00
- Total Liabilities: $5,041,434.00
- Total Equity: $3,867,226.00
- Current Assets: $1,051,292.00
- Current Liabilities: $4,513,309.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-9,813,601.00
- Gross Profit: $0.00
- Operating Income: $-10,054,488.00
- Earnings Per Share (EPS): -5.65

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Coeptis Therapeutics (COEP).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Coeptis Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because COEP is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for COEP.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, COEP could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect COEP to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Coeptis Therapeutics.

11) ETHICAL_RATING[]
Rate Coeptis Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Coeptis Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

COEP_IN_29 [2025-04-29 07:28:39 -0400] 126 Bytes | 29 tokens | Cum: 7089 tkns (88.61% of 8k)
==========================================================================

====================================
[2025-04-29 07:28:39] # Analysis Completed
Elapsed Time: 15.37 seconds